nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—HTR7—vein—ovarian cancer	0.0188	0.108	CbGeAlD
Asenapine—HTR2A—vein—ovarian cancer	0.0117	0.0673	CbGeAlD
Asenapine—HTR1E—myometrium—ovarian cancer	0.0102	0.0582	CbGeAlD
Asenapine—DRD4—testis—ovarian cancer	0.00554	0.0318	CbGeAlD
Asenapine—HTR1E—female gonad—ovarian cancer	0.00539	0.0309	CbGeAlD
Asenapine—HTR2B—myometrium—ovarian cancer	0.00433	0.0248	CbGeAlD
Asenapine—ADRA2C—myometrium—ovarian cancer	0.0034	0.0195	CbGeAlD
Asenapine—HTR2B—uterine cervix—ovarian cancer	0.00337	0.0193	CbGeAlD
Asenapine—HTR2B—decidua—ovarian cancer	0.00321	0.0184	CbGeAlD
Asenapine—HTR2B—endometrium—ovarian cancer	0.00304	0.0175	CbGeAlD
Asenapine—HTR7—epithelium—ovarian cancer	0.00291	0.0167	CbGeAlD
Asenapine—HTR2B—uterus—ovarian cancer	0.00281	0.0161	CbGeAlD
Asenapine—ADRA1A—epithelium—ovarian cancer	0.0028	0.0161	CbGeAlD
Asenapine—HTR1B—female reproductive system—ovarian cancer	0.0028	0.0161	CbGeAlD
Asenapine—HRH1—myometrium—ovarian cancer	0.00277	0.0159	CbGeAlD
Asenapine—ADRA2A—myometrium—ovarian cancer	0.00272	0.0156	CbGeAlD
Asenapine—HTR1D—female reproductive system—ovarian cancer	0.00271	0.0155	CbGeAlD
Asenapine—HTR2C—female reproductive system—ovarian cancer	0.00268	0.0154	CbGeAlD
Asenapine—ADRA2C—uterine cervix—ovarian cancer	0.00265	0.0152	CbGeAlD
Asenapine—ADRB1—female reproductive system—ovarian cancer	0.00263	0.0151	CbGeAlD
Asenapine—SLC6A4—female reproductive system—ovarian cancer	0.00254	0.0146	CbGeAlD
Asenapine—ADRA2C—decidua—ovarian cancer	0.00252	0.0145	CbGeAlD
Asenapine—HTR2B—female reproductive system—ovarian cancer	0.00252	0.0145	CbGeAlD
Asenapine—HRH2—lymph node—ovarian cancer	0.00248	0.0143	CbGeAlD
Asenapine—HTR7—gonad—ovarian cancer	0.00242	0.0139	CbGeAlD
Asenapine—ADRA2C—endometrium—ovarian cancer	0.0024	0.0137	CbGeAlD
Asenapine—HTR2B—vagina—ovarian cancer	0.00228	0.0131	CbGeAlD
Asenapine—HTR2A—embryo—ovarian cancer	0.00222	0.0127	CbGeAlD
Asenapine—ADRA2C—uterus—ovarian cancer	0.00221	0.0127	CbGeAlD
Asenapine—HRH1—epithelium—ovarian cancer	0.00217	0.0124	CbGeAlD
Asenapine—HTR7—female reproductive system—ovarian cancer	0.00216	0.0124	CbGeAlD
Asenapine—HRH1—uterine cervix—ovarian cancer	0.00215	0.0123	CbGeAlD
Asenapine—ADRA2A—uterine cervix—ovarian cancer	0.00211	0.0121	CbGeAlD
Asenapine—HRH1—decidua—ovarian cancer	0.00205	0.0118	CbGeAlD
Asenapine—ADRA2A—decidua—ovarian cancer	0.00201	0.0116	CbGeAlD
Asenapine—HRH1—endometrium—ovarian cancer	0.00195	0.0112	CbGeAlD
Asenapine—ADRA2A—endometrium—ovarian cancer	0.00191	0.011	CbGeAlD
Asenapine—HTR2A—epithelium—ovarian cancer	0.00181	0.0104	CbGeAlD
Asenapine—ADRA2C—female gonad—ovarian cancer	0.00181	0.0104	CbGeAlD
Asenapine—ADRA2C—vagina—ovarian cancer	0.0018	0.0103	CbGeAlD
Asenapine—ADRA2A—gonad—ovarian cancer	0.00177	0.0102	CbGeAlD
Asenapine—ADRA2A—uterus—ovarian cancer	0.00176	0.0101	CbGeAlD
Asenapine—HTR7—testis—ovarian cancer	0.00174	0.01	CbGeAlD
Asenapine—DRD2—testis—ovarian cancer	0.00165	0.00945	CbGeAlD
Asenapine—HRH1—female reproductive system—ovarian cancer	0.00161	0.00925	CbGeAlD
Asenapine—ADRA2C—testis—ovarian cancer	0.0016	0.00919	CbGeAlD
Asenapine—ADRA2A—female reproductive system—ovarian cancer	0.00158	0.00908	CbGeAlD
Asenapine—Mouth ulceration—Epirubicin—ovarian cancer	0.00153	0.0023	CcSEcCtD
Asenapine—Salivary hypersecretion—Doxorubicin—ovarian cancer	0.00152	0.00229	CcSEcCtD
Asenapine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00152	0.00228	CcSEcCtD
Asenapine—HTR2A—gonad—ovarian cancer	0.00151	0.00865	CbGeAlD
Asenapine—Skin exfoliation—Doxorubicin—ovarian cancer	0.0015	0.00225	CcSEcCtD
Asenapine—Asthenia—Chlorambucil—ovarian cancer	0.00148	0.00222	CcSEcCtD
Asenapine—Neutropenia—Docetaxel—ovarian cancer	0.00148	0.00221	CcSEcCtD
Asenapine—HTR2B—lymph node—ovarian cancer	0.00148	0.00846	CbGeAlD
Asenapine—Hypotension—Vinorelbine—ovarian cancer	0.00147	0.00221	CcSEcCtD
Asenapine—Oedema peripheral—Paclitaxel—ovarian cancer	0.00147	0.0022	CcSEcCtD
Asenapine—HRH1—female gonad—ovarian cancer	0.00147	0.00841	CbGeAlD
Asenapine—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00146	0.0022	CcSEcCtD
Asenapine—HRH1—vagina—ovarian cancer	0.00146	0.00836	CbGeAlD
Asenapine—ADRA2A—female gonad—ovarian cancer	0.00144	0.00827	CbGeAlD
Asenapine—Weight increased—Docetaxel—ovarian cancer	0.00144	0.00215	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00143	0.00215	CcSEcCtD
Asenapine—ADRA2A—vagina—ovarian cancer	0.00143	0.00821	CbGeAlD
Asenapine—Mouth ulceration—Doxorubicin—ovarian cancer	0.00142	0.00213	CcSEcCtD
Asenapine—Diabetes mellitus—Epirubicin—ovarian cancer	0.00142	0.00212	CcSEcCtD
Asenapine—Dyspnoea—Vinorelbine—ovarian cancer	0.0014	0.0021	CcSEcCtD
Asenapine—Eye disorder—Paclitaxel—ovarian cancer	0.00139	0.00209	CcSEcCtD
Asenapine—Cardiac disorder—Paclitaxel—ovarian cancer	0.00138	0.00207	CcSEcCtD
Asenapine—Stomatitis—Docetaxel—ovarian cancer	0.00137	0.00206	CcSEcCtD
Asenapine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00136	0.00204	CcSEcCtD
Asenapine—Fatigue—Vinorelbine—ovarian cancer	0.00136	0.00203	CcSEcCtD
Asenapine—Hypersensitivity—Topotecan—ovarian cancer	0.00136	0.00203	CcSEcCtD
Asenapine—Angiopathy—Paclitaxel—ovarian cancer	0.00135	0.00203	CcSEcCtD
Asenapine—HTR2A—female reproductive system—ovarian cancer	0.00135	0.00772	CbGeAlD
Asenapine—Constipation—Vinorelbine—ovarian cancer	0.00135	0.00202	CcSEcCtD
Asenapine—Immune system disorder—Paclitaxel—ovarian cancer	0.00135	0.00202	CcSEcCtD
Asenapine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00134	0.00201	CcSEcCtD
Asenapine—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00133	0.002	CcSEcCtD
Asenapine—Hypersensitivity—Melphalan—ovarian cancer	0.00133	0.00199	CcSEcCtD
Asenapine—Asthenia—Topotecan—ovarian cancer	0.00132	0.00198	CcSEcCtD
Asenapine—Vomiting—Chlorambucil—ovarian cancer	0.00131	0.00197	CcSEcCtD
Asenapine—Agranulocytosis—Docetaxel—ovarian cancer	0.00131	0.00197	CcSEcCtD
Asenapine—Increased appetite—Epirubicin—ovarian cancer	0.00131	0.00197	CcSEcCtD
Asenapine—Diabetes mellitus—Doxorubicin—ovarian cancer	0.00131	0.00196	CcSEcCtD
Asenapine—Mental disorder—Paclitaxel—ovarian cancer	0.00131	0.00196	CcSEcCtD
Asenapine—HRH1—testis—ovarian cancer	0.0013	0.00746	CbGeAlD
Asenapine—Malnutrition—Paclitaxel—ovarian cancer	0.0013	0.00194	CcSEcCtD
Asenapine—Asthenia—Melphalan—ovarian cancer	0.00129	0.00194	CcSEcCtD
Asenapine—Dermatitis bullous—Epirubicin—ovarian cancer	0.00129	0.00193	CcSEcCtD
Asenapine—ADRA2A—testis—ovarian cancer	0.00128	0.00733	CbGeAlD
Asenapine—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.00127	0.00191	CcSEcCtD
Asenapine—Dysgeusia—Paclitaxel—ovarian cancer	0.00127	0.0019	CcSEcCtD
Asenapine—Muscle spasms—Paclitaxel—ovarian cancer	0.00125	0.00187	CcSEcCtD
Asenapine—CYP3A4—female reproductive system—ovarian cancer	0.00125	0.00715	CbGeAlD
Asenapine—Oedema peripheral—Docetaxel—ovarian cancer	0.00124	0.00187	CcSEcCtD
Asenapine—Connective tissue disorder—Docetaxel—ovarian cancer	0.00124	0.00186	CcSEcCtD
Asenapine—Hyponatraemia—Epirubicin—ovarian cancer	0.00124	0.00185	CcSEcCtD
Asenapine—Pain in extremity—Epirubicin—ovarian cancer	0.00123	0.00185	CcSEcCtD
Asenapine—Osteoarthritis—Epirubicin—ovarian cancer	0.00123	0.00185	CcSEcCtD
Asenapine—Nausea—Chlorambucil—ovarian cancer	0.00123	0.00184	CcSEcCtD
Asenapine—CYP2D6—female reproductive system—ovarian cancer	0.00123	0.00704	CbGeAlD
Asenapine—HTR2A—vagina—ovarian cancer	0.00122	0.00698	CbGeAlD
Asenapine—Dizziness—Topotecan—ovarian cancer	0.00122	0.00182	CcSEcCtD
Asenapine—Tremor—Paclitaxel—ovarian cancer	0.00122	0.00182	CcSEcCtD
Asenapine—Increased appetite—Doxorubicin—ovarian cancer	0.00121	0.00182	CcSEcCtD
Asenapine—Anaemia—Paclitaxel—ovarian cancer	0.0012	0.0018	CcSEcCtD
Asenapine—Dermatitis bullous—Doxorubicin—ovarian cancer	0.00119	0.00179	CcSEcCtD
Asenapine—Agitation—Paclitaxel—ovarian cancer	0.00119	0.00179	CcSEcCtD
Asenapine—Angioedema—Paclitaxel—ovarian cancer	0.00119	0.00178	CcSEcCtD
Asenapine—Eye disorder—Docetaxel—ovarian cancer	0.00118	0.00177	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.00118	0.00177	CcSEcCtD
Asenapine—Cardiac disorder—Docetaxel—ovarian cancer	0.00117	0.00176	CcSEcCtD
Asenapine—Vomiting—Topotecan—ovarian cancer	0.00117	0.00175	CcSEcCtD
Asenapine—Malaise—Paclitaxel—ovarian cancer	0.00117	0.00175	CcSEcCtD
Asenapine—Syncope—Paclitaxel—ovarian cancer	0.00116	0.00174	CcSEcCtD
Asenapine—Leukopenia—Paclitaxel—ovarian cancer	0.00116	0.00174	CcSEcCtD
Asenapine—ADRA2C—lymph node—ovarian cancer	0.00116	0.00666	CbGeAlD
Asenapine—Rash—Topotecan—ovarian cancer	0.00116	0.00174	CcSEcCtD
Asenapine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00116	0.00174	CcSEcCtD
Asenapine—Dermatitis—Topotecan—ovarian cancer	0.00116	0.00174	CcSEcCtD
Asenapine—Headache—Topotecan—ovarian cancer	0.00115	0.00173	CcSEcCtD
Asenapine—Angiopathy—Docetaxel—ovarian cancer	0.00115	0.00172	CcSEcCtD
Asenapine—Vomiting—Melphalan—ovarian cancer	0.00115	0.00172	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—ovarian cancer	0.00114	0.00172	CcSEcCtD
Asenapine—Immune system disorder—Docetaxel—ovarian cancer	0.00114	0.00171	CcSEcCtD
Asenapine—Loss of consciousness—Paclitaxel—ovarian cancer	0.00114	0.00171	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—ovarian cancer	0.00114	0.00171	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—ovarian cancer	0.00114	0.00171	CcSEcCtD
Asenapine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00114	0.00171	CcSEcCtD
Asenapine—Rash—Melphalan—ovarian cancer	0.00114	0.0017	CcSEcCtD
Asenapine—Dermatitis—Melphalan—ovarian cancer	0.00114	0.0017	CcSEcCtD
Asenapine—Asthenia—Vinorelbine—ovarian cancer	0.00113	0.00169	CcSEcCtD
Asenapine—Orthostatic hypotension—Epirubicin—ovarian cancer	0.00113	0.00169	CcSEcCtD
Asenapine—Convulsion—Paclitaxel—ovarian cancer	0.00112	0.00169	CcSEcCtD
Asenapine—Hypertension—Paclitaxel—ovarian cancer	0.00112	0.00168	CcSEcCtD
Asenapine—CYP2D6—female gonad—ovarian cancer	0.00112	0.0064	CbGeAlD
Asenapine—Breast disorder—Epirubicin—ovarian cancer	0.00111	0.00167	CcSEcCtD
Asenapine—Mental disorder—Docetaxel—ovarian cancer	0.00111	0.00166	CcSEcCtD
Asenapine—Arthralgia—Paclitaxel—ovarian cancer	0.0011	0.00166	CcSEcCtD
Asenapine—Anxiety—Paclitaxel—ovarian cancer	0.0011	0.00165	CcSEcCtD
Asenapine—Malnutrition—Docetaxel—ovarian cancer	0.0011	0.00165	CcSEcCtD
Asenapine—Nausea—Topotecan—ovarian cancer	0.00109	0.00164	CcSEcCtD
Asenapine—HTR2A—testis—ovarian cancer	0.00109	0.00623	CbGeAlD
Asenapine—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00109	0.00163	CcSEcCtD
Asenapine—Dry mouth—Paclitaxel—ovarian cancer	0.00108	0.00162	CcSEcCtD
Asenapine—Dysgeusia—Docetaxel—ovarian cancer	0.00108	0.00161	CcSEcCtD
Asenapine—Nausea—Melphalan—ovarian cancer	0.00107	0.0016	CcSEcCtD
Asenapine—Dysphagia—Epirubicin—ovarian cancer	0.00106	0.0016	CcSEcCtD
Asenapine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00106	0.00159	CcSEcCtD
Asenapine—Muscle spasms—Docetaxel—ovarian cancer	0.00106	0.00158	CcSEcCtD
Asenapine—Shock—Paclitaxel—ovarian cancer	0.00104	0.00156	CcSEcCtD
Asenapine—Dizziness—Vinorelbine—ovarian cancer	0.00104	0.00156	CcSEcCtD
Asenapine—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.00104	0.00156	CcSEcCtD
Asenapine—Nervous system disorder—Paclitaxel—ovarian cancer	0.00104	0.00156	CcSEcCtD
Asenapine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00104	0.00155	CcSEcCtD
Asenapine—Tachycardia—Paclitaxel—ovarian cancer	0.00103	0.00155	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—ovarian cancer	0.00103	0.00154	CcSEcCtD
Asenapine—Anaemia—Docetaxel—ovarian cancer	0.00102	0.00152	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.00101	0.00151	CcSEcCtD
Asenapine—Vomiting—Vinorelbine—ovarian cancer	0.001	0.0015	CcSEcCtD
Asenapine—Neutropenia—Epirubicin—ovarian cancer	0.000996	0.00149	CcSEcCtD
Asenapine—Rash—Vinorelbine—ovarian cancer	0.000993	0.00149	CcSEcCtD
Asenapine—Dermatitis—Vinorelbine—ovarian cancer	0.000992	0.00149	CcSEcCtD
Asenapine—CYP2D6—testis—ovarian cancer	0.00099	0.00568	CbGeAlD
Asenapine—Hypotension—Paclitaxel—ovarian cancer	0.00099	0.00148	CcSEcCtD
Asenapine—Headache—Vinorelbine—ovarian cancer	0.000986	0.00148	CcSEcCtD
Asenapine—Syncope—Docetaxel—ovarian cancer	0.000986	0.00148	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—ovarian cancer	0.000985	0.00148	CcSEcCtD
Asenapine—Leukopenia—Docetaxel—ovarian cancer	0.000984	0.00148	CcSEcCtD
Asenapine—Weight increased—Epirubicin—ovarian cancer	0.000969	0.00145	CcSEcCtD
Asenapine—Loss of consciousness—Docetaxel—ovarian cancer	0.000967	0.00145	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000965	0.00145	CcSEcCtD
Asenapine—Hyperglycaemia—Epirubicin—ovarian cancer	0.00096	0.00144	CcSEcCtD
Asenapine—Insomnia—Paclitaxel—ovarian cancer	0.000958	0.00144	CcSEcCtD
Asenapine—Convulsion—Docetaxel—ovarian cancer	0.000953	0.00143	CcSEcCtD
Asenapine—Hypertension—Docetaxel—ovarian cancer	0.00095	0.00142	CcSEcCtD
Asenapine—Dyspnoea—Paclitaxel—ovarian cancer	0.000944	0.00142	CcSEcCtD
Asenapine—HRH1—lymph node—ovarian cancer	0.000943	0.00541	CbGeAlD
Asenapine—Somnolence—Paclitaxel—ovarian cancer	0.000941	0.00141	CcSEcCtD
Asenapine—Arthralgia—Docetaxel—ovarian cancer	0.000936	0.0014	CcSEcCtD
Asenapine—Nausea—Vinorelbine—ovarian cancer	0.000935	0.0014	CcSEcCtD
Asenapine—Dyspepsia—Paclitaxel—ovarian cancer	0.000932	0.0014	CcSEcCtD
Asenapine—ADRA2A—lymph node—ovarian cancer	0.000926	0.00531	CbGeAlD
Asenapine—Stomatitis—Epirubicin—ovarian cancer	0.000925	0.00139	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—ovarian cancer	0.000921	0.00138	CcSEcCtD
Asenapine—Dry mouth—Docetaxel—ovarian cancer	0.000916	0.00137	CcSEcCtD
Asenapine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000914	0.00137	CcSEcCtD
Asenapine—Fatigue—Paclitaxel—ovarian cancer	0.000913	0.00137	CcSEcCtD
Asenapine—Constipation—Paclitaxel—ovarian cancer	0.000906	0.00136	CcSEcCtD
Asenapine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000898	0.00135	CcSEcCtD
Asenapine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000898	0.00135	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—ovarian cancer	0.000896	0.00134	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000889	0.00133	CcSEcCtD
Asenapine—Agranulocytosis—Epirubicin—ovarian cancer	0.000886	0.00133	CcSEcCtD
Asenapine—Shock—Docetaxel—ovarian cancer	0.000883	0.00132	CcSEcCtD
Asenapine—Nervous system disorder—Docetaxel—ovarian cancer	0.00088	0.00132	CcSEcCtD
Asenapine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000879	0.00132	CcSEcCtD
Asenapine—Tachycardia—Docetaxel—ovarian cancer	0.000876	0.00131	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—ovarian cancer	0.000856	0.00128	CcSEcCtD
Asenapine—Oedema peripheral—Epirubicin—ovarian cancer	0.000839	0.00126	CcSEcCtD
Asenapine—Hypotension—Docetaxel—ovarian cancer	0.000839	0.00126	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000837	0.00126	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000831	0.00125	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—ovarian cancer	0.00082	0.00123	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000818	0.00123	CcSEcCtD
Asenapine—Insomnia—Docetaxel—ovarian cancer	0.000812	0.00122	CcSEcCtD
Asenapine—Dyspnoea—Docetaxel—ovarian cancer	0.0008	0.0012	CcSEcCtD
Asenapine—Somnolence—Docetaxel—ovarian cancer	0.000798	0.0012	CcSEcCtD
Asenapine—Eye disorder—Epirubicin—ovarian cancer	0.000796	0.00119	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—ovarian cancer	0.000791	0.00119	CcSEcCtD
Asenapine—Dyspepsia—Docetaxel—ovarian cancer	0.00079	0.00118	CcSEcCtD
Asenapine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00078	0.00117	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—ovarian cancer	0.000777	0.00116	CcSEcCtD
Asenapine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000775	0.00116	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000775	0.00116	CcSEcCtD
Asenapine—Fatigue—Docetaxel—ovarian cancer	0.000774	0.00116	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—ovarian cancer	0.000773	0.00116	CcSEcCtD
Asenapine—Immune system disorder—Epirubicin—ovarian cancer	0.00077	0.00115	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000768	0.00115	CcSEcCtD
Asenapine—Constipation—Docetaxel—ovarian cancer	0.000768	0.00115	CcSEcCtD
Asenapine—Asthenia—Paclitaxel—ovarian cancer	0.00076	0.00114	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—ovarian cancer	0.000747	0.00112	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—ovarian cancer	0.000742	0.00111	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—ovarian cancer	0.000737	0.0011	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000732	0.0011	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—ovarian cancer	0.000726	0.00109	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—ovarian cancer	0.000715	0.00107	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—ovarian cancer	0.000713	0.00107	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—ovarian cancer	0.000712	0.00107	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000711	0.00107	CcSEcCtD
Asenapine—Dizziness—Paclitaxel—ovarian cancer	0.0007	0.00105	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—ovarian cancer	0.000691	0.00104	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—ovarian cancer	0.000686	0.00103	CcSEcCtD
Asenapine—Anaemia—Epirubicin—ovarian cancer	0.000686	0.00103	CcSEcCtD
Asenapine—Agitation—Epirubicin—ovarian cancer	0.000682	0.00102	CcSEcCtD
Asenapine—Vomiting—Paclitaxel—ovarian cancer	0.000673	0.00101	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—ovarian cancer	0.000672	0.00101	CcSEcCtD
Asenapine—Malaise—Epirubicin—ovarian cancer	0.000669	0.001	CcSEcCtD
Asenapine—Rash—Paclitaxel—ovarian cancer	0.000668	0.001	CcSEcCtD
Asenapine—Dermatitis—Paclitaxel—ovarian cancer	0.000667	0.001	CcSEcCtD
Asenapine—Syncope—Epirubicin—ovarian cancer	0.000665	0.000997	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—ovarian cancer	0.000664	0.000995	CcSEcCtD
Asenapine—Headache—Paclitaxel—ovarian cancer	0.000663	0.000994	CcSEcCtD
Asenapine—Hypersensitivity—Docetaxel—ovarian cancer	0.000661	0.000991	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—ovarian cancer	0.00066	0.000989	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—ovarian cancer	0.000652	0.000977	CcSEcCtD
Asenapine—Asthenia—Docetaxel—ovarian cancer	0.000644	0.000965	CcSEcCtD
Asenapine—Convulsion—Epirubicin—ovarian cancer	0.000643	0.000963	CcSEcCtD
Asenapine—Hypertension—Epirubicin—ovarian cancer	0.00064	0.00096	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—ovarian cancer	0.000634	0.000951	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—ovarian cancer	0.000632	0.000947	CcSEcCtD
Asenapine—Agitation—Doxorubicin—ovarian cancer	0.000631	0.000945	CcSEcCtD
Asenapine—Anxiety—Epirubicin—ovarian cancer	0.000629	0.000943	CcSEcCtD
Asenapine—Nausea—Paclitaxel—ovarian cancer	0.000629	0.000943	CcSEcCtD
Asenapine—Malaise—Doxorubicin—ovarian cancer	0.000619	0.000928	CcSEcCtD
Asenapine—Dry mouth—Epirubicin—ovarian cancer	0.000618	0.000926	CcSEcCtD
Asenapine—Syncope—Doxorubicin—ovarian cancer	0.000616	0.000923	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—ovarian cancer	0.000614	0.000921	CcSEcCtD
Asenapine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000605	0.000907	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000603	0.000904	CcSEcCtD
Asenapine—Shock—Epirubicin—ovarian cancer	0.000596	0.000893	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—ovarian cancer	0.000595	0.000891	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—ovarian cancer	0.000594	0.00089	CcSEcCtD
Asenapine—Dizziness—Docetaxel—ovarian cancer	0.000594	0.00089	CcSEcCtD
Asenapine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000593	0.000889	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—ovarian cancer	0.000593	0.000888	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—ovarian cancer	0.000591	0.000886	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—ovarian cancer	0.000584	0.000876	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—ovarian cancer	0.000582	0.000873	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—ovarian cancer	0.000571	0.000857	CcSEcCtD
Asenapine—Vomiting—Docetaxel—ovarian cancer	0.000571	0.000855	CcSEcCtD
Asenapine—Rash—Docetaxel—ovarian cancer	0.000566	0.000848	CcSEcCtD
Asenapine—Hypotension—Epirubicin—ovarian cancer	0.000566	0.000848	CcSEcCtD
Asenapine—Dermatitis—Docetaxel—ovarian cancer	0.000565	0.000848	CcSEcCtD
Asenapine—Headache—Docetaxel—ovarian cancer	0.000562	0.000843	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.00056	0.00084	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000552	0.000827	CcSEcCtD
Asenapine—Shock—Doxorubicin—ovarian cancer	0.000551	0.000826	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000549	0.000823	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000548	0.000822	CcSEcCtD
Asenapine—Insomnia—Epirubicin—ovarian cancer	0.000548	0.000821	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—ovarian cancer	0.000547	0.000819	CcSEcCtD
Asenapine—Dyspnoea—Epirubicin—ovarian cancer	0.00054	0.000809	CcSEcCtD
Asenapine—Somnolence—Epirubicin—ovarian cancer	0.000538	0.000807	CcSEcCtD
Asenapine—Nausea—Docetaxel—ovarian cancer	0.000533	0.000799	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—ovarian cancer	0.000533	0.000799	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—ovarian cancer	0.000523	0.000785	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000523	0.000783	CcSEcCtD
Asenapine—Fatigue—Epirubicin—ovarian cancer	0.000522	0.000782	CcSEcCtD
Asenapine—Constipation—Epirubicin—ovarian cancer	0.000518	0.000776	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00051	0.000765	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—ovarian cancer	0.000507	0.000759	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—ovarian cancer	0.000499	0.000749	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—ovarian cancer	0.000498	0.000746	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—ovarian cancer	0.000493	0.000739	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000484	0.000725	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—ovarian cancer	0.000483	0.000724	CcSEcCtD
Asenapine—Constipation—Doxorubicin—ovarian cancer	0.000479	0.000718	CcSEcCtD
Asenapine—Hypersensitivity—Epirubicin—ovarian cancer	0.000446	0.000669	CcSEcCtD
Asenapine—Asthenia—Epirubicin—ovarian cancer	0.000434	0.000651	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000413	0.000619	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—ovarian cancer	0.000402	0.000602	CcSEcCtD
Asenapine—Dizziness—Epirubicin—ovarian cancer	0.0004	0.0006	CcSEcCtD
Asenapine—Vomiting—Epirubicin—ovarian cancer	0.000385	0.000577	CcSEcCtD
Asenapine—Rash—Epirubicin—ovarian cancer	0.000382	0.000572	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—ovarian cancer	0.000381	0.000572	CcSEcCtD
Asenapine—Headache—Epirubicin—ovarian cancer	0.000379	0.000569	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—ovarian cancer	0.00037	0.000555	CcSEcCtD
Asenapine—Nausea—Epirubicin—ovarian cancer	0.00036	0.000539	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—ovarian cancer	0.000356	0.000534	CcSEcCtD
Asenapine—Rash—Doxorubicin—ovarian cancer	0.000353	0.000529	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—ovarian cancer	0.000353	0.000529	CcSEcCtD
Asenapine—Headache—Doxorubicin—ovarian cancer	0.000351	0.000526	CcSEcCtD
Asenapine—Nausea—Doxorubicin—ovarian cancer	0.000333	0.000499	CcSEcCtD
Asenapine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.38e-05	8.69e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	1.38e-05	8.68e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	1.38e-05	8.68e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—ovarian cancer	1.37e-05	8.66e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	1.37e-05	8.66e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—ovarian cancer	1.37e-05	8.65e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	1.37e-05	8.64e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	1.37e-05	8.63e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL2—ovarian cancer	1.37e-05	8.62e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CASP3—ovarian cancer	1.37e-05	8.62e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL2—ovarian cancer	1.36e-05	8.6e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—ovarian cancer	1.36e-05	8.59e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—STAT3—ovarian cancer	1.36e-05	8.59e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	1.36e-05	8.58e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—NRAS—ovarian cancer	1.36e-05	8.57e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—IL6—ovarian cancer	1.36e-05	8.56e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	1.36e-05	8.56e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.35e-05	8.54e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	1.35e-05	8.54e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	1.35e-05	8.54e-05	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	1.35e-05	8.54e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.35e-05	8.49e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	1.34e-05	8.48e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.34e-05	8.46e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	1.34e-05	8.46e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	1.34e-05	8.44e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.34e-05	8.44e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—ovarian cancer	1.33e-05	8.41e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	1.33e-05	8.41e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	1.33e-05	8.4e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—STAT3—ovarian cancer	1.33e-05	8.4e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	1.33e-05	8.39e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.33e-05	8.39e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—ovarian cancer	1.33e-05	8.39e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—ovarian cancer	1.33e-05	8.38e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.32e-05	8.36e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.32e-05	8.34e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.32e-05	8.32e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	1.32e-05	8.31e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.32e-05	8.31e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.31e-05	8.29e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—ovarian cancer	1.31e-05	8.28e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—ovarian cancer	1.31e-05	8.28e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.31e-05	8.27e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—ovarian cancer	1.31e-05	8.27e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.31e-05	8.25e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	1.3e-05	8.23e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—ovarian cancer	1.3e-05	8.22e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	1.3e-05	8.21e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	1.3e-05	8.21e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	1.3e-05	8.21e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	1.3e-05	8.17e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.29e-05	8.16e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—ovarian cancer	1.29e-05	8.16e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	1.29e-05	8.16e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	1.29e-05	8.15e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.29e-05	8.14e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	1.29e-05	8.13e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.29e-05	8.11e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	1.29e-05	8.11e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.28e-05	8.1e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	1.28e-05	8.09e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CAV1—ovarian cancer	1.28e-05	8.08e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—ovarian cancer	1.28e-05	8.05e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.28e-05	8.04e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	1.27e-05	8.02e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.27e-05	8.02e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	1.27e-05	7.99e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.27e-05	7.98e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	1.27e-05	7.98e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—ovarian cancer	1.27e-05	7.98e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EGFR—ovarian cancer	1.27e-05	7.98e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	1.26e-05	7.94e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.26e-05	7.93e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—IL6—ovarian cancer	1.26e-05	7.93e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—ovarian cancer	1.26e-05	7.92e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—IL6—ovarian cancer	1.25e-05	7.92e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.25e-05	7.92e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	1.25e-05	7.91e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	1.25e-05	7.91e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—ovarian cancer	1.25e-05	7.9e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.25e-05	7.9e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.25e-05	7.88e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—IL6—ovarian cancer	1.25e-05	7.87e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	1.25e-05	7.86e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	1.24e-05	7.85e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	1.24e-05	7.81e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EGFR—ovarian cancer	1.24e-05	7.81e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	1.24e-05	7.81e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—ovarian cancer	1.24e-05	7.81e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	1.23e-05	7.77e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.23e-05	7.76e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	1.23e-05	7.75e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—TYMS—ovarian cancer	1.23e-05	7.74e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.22e-05	7.72e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	1.22e-05	7.71e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—IL6—ovarian cancer	1.22e-05	7.7e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	1.22e-05	7.67e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.21e-05	7.65e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.21e-05	7.64e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	1.21e-05	7.64e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EGFR—ovarian cancer	1.21e-05	7.63e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.21e-05	7.6e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.2e-05	7.6e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.2e-05	7.59e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—IL6—ovarian cancer	1.2e-05	7.58e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.2e-05	7.57e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—ovarian cancer	1.2e-05	7.56e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	1.2e-05	7.55e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—ovarian cancer	1.2e-05	7.54e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	1.18e-05	7.47e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—ovarian cancer	1.18e-05	7.45e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.18e-05	7.45e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.18e-05	7.43e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	1.17e-05	7.39e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	1.17e-05	7.39e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.17e-05	7.38e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—ovarian cancer	1.17e-05	7.38e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.17e-05	7.37e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.17e-05	7.36e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.17e-05	7.36e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—ovarian cancer	1.17e-05	7.35e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.16e-05	7.33e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.16e-05	7.31e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.16e-05	7.31e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—ovarian cancer	1.16e-05	7.3e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.15e-05	7.26e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—ovarian cancer	1.15e-05	7.26e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.15e-05	7.24e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.15e-05	7.24e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—IL6—ovarian cancer	1.15e-05	7.23e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.14e-05	7.22e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.14e-05	7.21e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.14e-05	7.2e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	1.14e-05	7.18e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.14e-05	7.17e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.13e-05	7.13e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—ovarian cancer	1.13e-05	7.11e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	1.13e-05	7.11e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	1.12e-05	7.09e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.12e-05	7.05e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—ovarian cancer	1.11e-05	7.03e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—ovarian cancer	1.11e-05	6.99e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	1.11e-05	6.98e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.1e-05	6.93e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	1.1e-05	6.93e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.1e-05	6.92e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	1.09e-05	6.86e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—ovarian cancer	1.09e-05	6.85e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—IL6—ovarian cancer	1.08e-05	6.82e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.08e-05	6.79e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	1.07e-05	6.78e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.07e-05	6.74e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—IL6—ovarian cancer	1.07e-05	6.73e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—ovarian cancer	1.07e-05	6.73e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.06e-05	6.7e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.06e-05	6.7e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—ovarian cancer	1.06e-05	6.7e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—ovarian cancer	1.06e-05	6.67e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.06e-05	6.67e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.06e-05	6.66e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	1.05e-05	6.64e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.05e-05	6.63e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.05e-05	6.6e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.05e-05	6.6e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.05e-05	6.6e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.05e-05	6.6e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.04e-05	6.59e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.04e-05	6.59e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.04e-05	6.58e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.04e-05	6.58e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—ovarian cancer	1.04e-05	6.56e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.03e-05	6.47e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1.02e-05	6.46e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1.02e-05	6.46e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	1.02e-05	6.41e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.02e-05	6.41e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—ovarian cancer	1.02e-05	6.41e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.01e-05	6.38e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	1.01e-05	6.35e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—ovarian cancer	1e-05	6.33e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1e-05	6.31e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—ovarian cancer	9.98e-06	6.29e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—ovarian cancer	9.94e-06	6.27e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—ovarian cancer	9.93e-06	6.26e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CAV1—ovarian cancer	9.88e-06	6.24e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	9.88e-06	6.23e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	9.87e-06	6.23e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—ovarian cancer	9.85e-06	6.22e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—ovarian cancer	9.84e-06	6.21e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	9.83e-06	6.2e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	9.72e-06	6.13e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL6—ovarian cancer	9.72e-06	6.13e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—ovarian cancer	9.72e-06	6.13e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	9.67e-06	6.1e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	9.67e-06	6.1e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	9.63e-06	6.08e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	9.51e-06	6e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL6—ovarian cancer	9.51e-06	6e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	9.51e-06	6e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	9.4e-06	5.93e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL6—ovarian cancer	9.3e-06	5.87e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL6—ovarian cancer	9.25e-06	5.84e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	9.22e-06	5.82e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—ovarian cancer	9.12e-06	5.75e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	9.07e-06	5.72e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	9.05e-06	5.71e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	9e-06	5.68e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	9e-06	5.68e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	8.98e-06	5.67e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—ovarian cancer	8.97e-06	5.66e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	8.94e-06	5.64e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—ovarian cancer	8.92e-06	5.63e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	8.89e-06	5.61e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	8.88e-06	5.6e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—ovarian cancer	8.78e-06	5.54e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—ovarian cancer	8.77e-06	5.54e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—ovarian cancer	8.76e-06	5.53e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	8.59e-06	5.42e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—ovarian cancer	8.58e-06	5.41e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	8.54e-06	5.38e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—ovarian cancer	8.53e-06	5.38e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	8.39e-06	5.3e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—ovarian cancer	8.38e-06	5.28e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	8.3e-06	5.24e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	8.25e-06	5.21e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	8.22e-06	5.19e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL6—ovarian cancer	8.17e-06	5.15e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—ovarian cancer	8.06e-06	5.09e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL6—ovarian cancer	8.03e-06	5.07e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL6—ovarian cancer	8.02e-06	5.06e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	7.99e-06	5.04e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	7.92e-06	4.99e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	7.87e-06	4.96e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—ovarian cancer	7.72e-06	4.87e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	7.64e-06	4.82e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—ovarian cancer	7.53e-06	4.75e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	7.41e-06	4.68e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—ovarian cancer	7.4e-06	4.67e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	7.31e-06	4.61e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	7.26e-06	4.58e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	6.9e-06	4.35e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	6.74e-06	4.25e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	6.43e-06	4.06e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—ovarian cancer	5.96e-06	3.76e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	5.45e-06	3.44e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—ovarian cancer	5.26e-06	3.32e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—ovarian cancer	4.45e-06	2.81e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.21e-06	2.65e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—ovarian cancer	3.44e-06	2.17e-05	CbGpPWpGaD
